
    
      The primary objective of the study is to characterize the biotransformation and excretion of
      [14C]-CC-90009 following a single intravenous (IV) dose of 0.6 mg [14C]-CC-90009 in healthy
      male subjects. The secondary objective of the study is to evaluate the safety and
      tolerability. The total radioactivity of [14C]-CC-90009 will be 2 Î¼Ci.
    
  